• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: CHRISTOPH MIETHKE GMBH & CO KG PROGAV 2.0 W/SA2.0 25 & PED.PRECHAMBER; HYDROCEPHALUS MANAGEMENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

CHRISTOPH MIETHKE GMBH & CO KG PROGAV 2.0 W/SA2.0 25 & PED.PRECHAMBER; HYDROCEPHALUS MANAGEMENT Back to Search Results
Model Number FX661T
Medical Device Problem Codes Mechanical Problem (1384); Infusion or Flow Problem (2964)
Health Effect - Clinical Code Hydrocephalus (3272)
Date of Event 05/23/2021
Type of Reportable Event Serious Injury
Additional Manufacturer Narrative
Investigation: visual inspection: no significant deformations or damage of the valves were detected during the visual inspection.Permeability test: a permeability test has shown that both valves are permeable.Bloody liquid drained flushed out.Computer controlled test: to investigate the claim of under-drainage, the opening pressure is measured using a miethke computer controlled testing apparatus which simulates a cerebrospinal fluid flow.The valves are tested in both the horizontal as well as the vertical positions.The results show that the progav 2.0 is operating within the accepted tolerance in the horizontal position.The shuntassistant 2.0 is operating not within the specified tolerances in the vertical position.Adjustment test: the progav 2.0 was tested and is adjustable to all specified pressures.Braking force and brake function test: the brake functionality test has shown that the brake function is fully operational and the braking force is within the given tolerances.Results: first, we performed a visual inspection of the progav 2.0 shunt system.No significant deformations or damage of the valves were detected during the visual inspection.Next, we tested the permeability, adjustability, and opening pressure of the valve, as well as the brake functionality and brake force.The opening pressure of the shuntassistant 2.0 was out of tolerance, but all other specifications were met.The shuntassistant 2.0 showed a slightly accelerated outflow.Finally, we have dismantled the valves.Inside the progav 2.0 we have found slight build-up of substances (likely protein), in the shuntassistant 2.0 we have found no visible deposits.Based on our investigation, we are unable to substantiate the clinical claim of non-adjustability.At the time of our investigation, the valve was able to be adjusted to all specified settings.The shuntassistant 2.0 showed an accelerated outflow.However, it is possible that the deposits observed inside the valve could have caused the malfunction in the past.As described in scientific literature, the problem encountered is one of the known, inevitable risks of hc-therapy by shunt implants.We can exclude a defect at the time of release.The shunt system met all specifications of the final inspection when released from christoph miethke gmbh & co.Kg.No further regulatory actions are required from our point of view.
 
Event or Problem Description
It was reported that a progav 2.0 shuntsytsem (#fx661t) was implanted during a procedure performed in (b)(6) 2021.According to the complainant, the valve was believed to be operated in underdrainage and is not further- adjustable.The ventricular catheter was clogged.The patient underwent a revision procedure.The complainant device was returned to the manufacturer for evaluation.No patient complications were reported as a result of the revision procedure.Age: (b)(6) height: unknown weight: (b)(6) gender: female.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
PROGAV 2.0 W/SA2.0 25 & PED.PRECHAMBER
Common Device Name
HYDROCEPHALUS MANAGEMENT
Manufacturer (Section D)
CHRISTOPH MIETHKE GMBH & CO KG
ulanenweg 2
potsdam, 14469
GM  14469
MDR Report Key12012578
Report Number3004721439-2021-00168
Device Sequence Number17225599
Product Code JXG
UDI-Device Identifier04041906503802
UDI-Public4041906503802
Combination Product (Y/N)N
Initial Reporter CountryGM
PMA/510(K) Number
K190174
Number of Events Summarized1
Summary Report (Y/N)N
Device Explanted Year2021
Serviced by Third Party (Y/N)N
Reporter Type Manufacturer
Report Source company representative,user f
Initial Reporter Occupation Physician
Type of Report Initial
Report Date (Section B) 06/14/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Device Expiration Date01/17/2026
Device Model NumberFX661T
Device Catalogue NumberFX661T
Device Lot Number20051313
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer05/28/2021
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 05/28/2021
Initial Report FDA Received Date06/16/2021
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Patient Sequence Number1
Outcome Attributed to Adverse Event Required Intervention;
Patient Age33 MO
Patient Weight11
-
-